fbpx
vitiligo

Individuals who have a diagnosis of non-segmental vitiligo may qualify for this clinical research trial and receive investigational oral medication (Ritlecitinib) or placebo.

  • Age: ≥ 12 years old
  • Vitiligo for ≥3 months
  • BSA 4% - 60% and facial BSA ≥ 0.5%
  • Fitzpatrick skin type V-VI for adults
  • All Fitzpatrick skin types for adolescents
  • No prior exposure to JAKi or surgical treatment for vitiligo

Patients will be asked to visit the clinic about 11 times over approximately 60 weeks. There is no cost to participate, and participants will be reimbursed for their time and travel.

For further information on the study, please follow the link:

Study Details | A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo | ClinicalTrials.gov

Trial ID: NCT05583526

If you are interested in participating in a vitiligo clinical trial, please submit your details and our team will be in touch: expression of interest form

 

Accreditations & Memberships

Australasian Hair and Wool Research Society
victoria
international academy cosmetic dermatology
european medecines agency
gpce
deakin university
congress dermatology
bellberry limted
australiasian college dermatologists
australian government national health
australian government ip
australian clinical trials
asdr
albinism fellowship australia
aaaf
ahsf
american dermatological association
british association of dermatology
epworth
international society of dermatology
university of melbourne
Book Appointment
Shop